| 发明名称 | Methods of determination of activation or inactivation of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) hormonal systems | ||
| 摘要 | An in vivo method of determining activation or inactivation of the atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) hormonal systems, the method comprising simultaneously detecting the presence or amount of atrial and brain natriuretic peptide prohormones (proANP and proBNP) or fragments thereof in a sample. | ||
| 申请公布号 | US9151766(B2) | 申请公布日期 | 2015.10.06 |
| 申请号 | US201213633992 | 申请日期 | 2012.10.03 |
| 申请人 | Orion Diagnostics Oy | 发明人 | Vuolteenaho Olli;Ala-Kopsala Minna;Ruskoaho Heikki;Leppäluoto Juhani;Haapalahti Jouko |
| 分类号 | A61K38/00;C07K1/00;G01N33/74;C07K16/26;G01N33/68;C07K14/47;C07K16/18 | 主分类号 | A61K38/00 |
| 代理机构 | Clark & Elbing LLP | 代理人 | Clark & Elbing LLP ;Michaud Susan M. |
| 主权项 | 1. An agent which comprises a fusion polypeptide comprising: (a) (i) atrial natriuretic protein prohormone (pro-ANP; SEQ ID NO:1), ANP (SEQ ID NO:2), or NT-proANP (SEQ ID NO:3); (ii) a homologous sequence having at least 70% identity to (a)(i); or(iii) a fragment of (a)(i) or (a)(ii) which is at least 6 amino acids in length; and (b) (i) brain natriuretic protein prohormone (pro-BNP; SEQ ID NO:4), BNP (SEQ ID NO:5), or NT-proBNP (SEQ ID NO:6); (ii) a homologous sequence having at least 70% identity to (b)(i); or(iii) a fragment of (b)(i) or (b)(ii) which is at least 6 amino acids in length. | ||
| 地址 | Espoo FI | ||